Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 7/20 | 0.54 |
| ▸ | MEN1 | O00255 | 4/20 | 0.47 |
| ▸ | EDNRA | P25101 | 1/20 | 0.44 |
| ▸ | GFER | P55789 | 2/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | GPR55 | Q9Y2T6 | 2/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | HTR1A | P08908 | 1/20 | 0.42 |
| ▸ | CNR1 | P21554 | 1/20 | 0.42 |
| ▸ | HTR7 | P34969 | 1/20 | 0.42 |
| ▸ | HTR6 | P50406 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | BLM | P54132 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | MGLL | Q99685 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8152135 | 0.82 | KMT2A (0.57) | KMT2AMEN1EDNRAGFERPOLB | |
| SCHEMBL4998200 | 0.77 | KMT2A (0.48) | KMT2AMEN1EDNRASMN1; SMN2ALDH1A1 | |
| SCHEMBL4995400 | 0.75 | KMT2A (0.47) | KMT2AMEN1EDNRASMN1; SMN2LMNA | |
| SCHEMBL7831531 | 0.75 | MAPT (0.52) | KMT2AMEN1POLBSMN1; SMN2ALDH1A1 | |
| SCHEMBL7842141 | 0.74 | KMT2A (0.58) | KMT2AMEN1EDNRAPOLBSMN1; SMN2 | |
| SCHEMBL7295115 | 0.73 | GAA (0.48) | KMT2AMEN1EDNRAPOLBTP53 | |
| SCHEMBL6138702 | 0.73 | RAB9A (0.56) | KMT2AMEN1EDNRASMN1; SMN2ALDH1A1 | |
| SCHEMBL7839624 | 0.73 | KMT2A (0.48) | KMT2AMEN1EDNRAPOLBALDH1A1 | |
| SCHEMBL7841623 | 0.72 | KMT2A (0.44) | KMT2AMEN1EDNRAPOLBSMN1; SMN2 | |
| SCHEMBL7842489 | 0.72 | RAB9A (0.44) | KMT2AMEN1ALDH1A1HTTNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7365093-B2 | Endothelin antagonists | ABBOTT LABORATORIES (US) | 2008-04-29 | — | — | US | disclosed |
| US-7208517-B1 | Endothelin antagonists | ABBOTT LABORTORIES (US) | 2007-04-24 | — | — | US | disclosed |
| US-20060229280-A1 | Endothelin antagonists | ABBVIE INC. | 2006-10-12 | — | — | US | disclosed |
| EP-0885215-B1 | NOVEL BENZO-1,3-DIOXOLYL- AND BENZOFURANYL SUBSTITUTED PYRROLIDINE DERIVATIVES AS ENDOTHELIN ANTAGONISTS | ABBOTT LAB (US) | 2006-04-19 | — | — | EP | disclosed |
| EP-1609790-A2 | Benzo-1,3-dioxolyl- and benzofuranyl substituted pyrrolidine derivatives as endothelin antagonists | Abbott Laboratories (US) | 2005-12-28 | — | — | EP | disclosed |
| US-6946481-B1 | Endothelin antagonists | ABBOTT LABORATORIES (US) | 2005-09-20 | — | — | US | disclosed |
| US-6462194-B1 | Endothelin antagonists | ABBOTT LABORATORIES | 2002-10-08 | — | — | US | disclosed |
| EP-0776324-B1 | ENDOTHELIN ANTAGONISTS | ABBOTT LAB (US) | 2002-06-12 | — | — | EP | disclosed |
| US-6380241-B1 | FOR THERAPY OF CORONARY ANGINA, CEREBRAL VASOSPASM, ACUTE AND CHRONIC RENAL FAILURE, GASTRIC ULCERATION, CYCLOSPORIN-INDUCED NEPHROTOXICITY, ENDOTOXIN-INDUCED TOXICITY, ASTHMA, LPL-RELATED LIPOPROTEIN DISORDERS, PROLIFERATIVE DISEASES | ABBOTT LABORATORIES | 2002-04-30 | — | — | US | disclosed |
| EP-1186603-A2 | Processes for preparing endothelin antagonists | Abbott Laboratories (US) | 2002-03-13 | — | — | EP | disclosed |
| US-6162927-A | Endothelin antagonists | ABBOTT LABORATORIES (US) | 2000-12-19 | — | — | US | disclosed |
| US-5767144-A | Endothelin antagonists | ABBOTT LABORATORIES (US) | 1998-06-16 | — | — | US | disclosed |
| US-5731434-A | CARDIOVASCULAR DISORDERS | ABBOTT LABORATORIES (US) | 1998-03-24 | — | — | US | disclosed |
| WO-1996006095-A1 | ENDOTHELIN ANTAGONISTS | ABBOTT LABORATORIES (US) | 1996-02-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060229280-A1 | Endothelin antagonists | EDNRA, EDNRB, ECE1 | KMT2A 3752/4885MEN1 517/4885EDNRA 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.